Home World News Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with... World News Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma By Ogkologos - July 9, 2026 145 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SUCCESSOR-2 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated... February 18, 2026 Many Patients with NSCLC Show Targetable Alterations in the PI3K Pathway March 24, 2021 Holiday Travel: 11 Things To Know Before Hitting The Road With... November 20, 2019 Integrating Geriatric Assessment into Cancer Care: A Conversation with Dr. Supriya... September 11, 2018 Load more HOT NEWS Take with Food: Study Tests Lowering Dose of Prostate Cancer Drug Activity and Safety of Regorafenib Plus Nivolumab in First-Line Treatment for... COVID-19 Vaccine: Distribution and Administration COVID-19 in people with cancer – what we know so far
